Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2024 Sep 25;110(20):1201-1207.
doi: 10.1136/heartjnl-2022-322030.

Treating iron deficiency in patients with heart failure: what, why, when, how, where and who

Affiliations
Review

Treating iron deficiency in patients with heart failure: what, why, when, how, where and who

Fraser J Graham et al. Heart. .

Abstract

For patients with heart failure and reduced or mildly reduced left ventricular ejection fraction, iron deficiency is common and associated with more severe symptoms, worse quality of life and an increased risk of hospitalisations and death. Iron deficiency can be swiftly, effectively and safely treated by administering intravenous iron, either as ferric carboxymaltose or ferric derisomaltose, which improves patient well-being and reduces the risk of hospitalisations including those for heart failure. However, the current definition of iron deficiency in heart failure has serious flaws. A serum ferritin <100 µg/L does not identify patients more likely to respond to intravenous iron. In contrast, patients with transferrin saturations <20%, most of whom are also anaemic, are more likely to have a beneficial response to intravenous iron. In this review, we summarise the available evidence for use of intravenous iron in heart failure and provide recommendations for targeted future research and practical considerations for the general cardiologist.

Keywords: Biomarkers; Heart Failure, Systolic; Pharmacology, Clinical.

PubMed Disclaimer

Conflict of interest statement

Competing interests: FJG reports receipt of sponsorship from Pharmacosmos to attend an international meeting and consultancy fees from Vifor. KG has received honoraria from Novartis, AstraZeneca, Pfizer, Bayer, Boehringer Ingelheim and Servier Laboratories. JGC reports receipt of personal honoraria for lectures and advisory boards from Pharmacosmos and Vifor, and from AstraZeneca, Amgen, Bayer, Novartis and Servier. The University of Glasgow has received research grants from Pharmacosmos and Vifor. PRK reports consulting fees from Amgen, Bayer, Boehringer Ingelheim, Pharmacosmos and CSL Vifor; payment for lectures from AstraZeneca, Bayer, Novartis, Pfizer, Pharmacosmos and CSL Vifor; and support for attending meetings from Pharmacosmos.

Figures

Figure 1
Figure 1. Stepwise guidance on how to assess, diagnose, manage and monitor patients with heart failure and iron deficiency. Abbreviations:- HF: heart failure; HFrEF: heart failure with reduced ejection fraction; HFmrEF: heart failure with mildly reduced ejection; TSAT: transferrin saturation; IV: intravenous; Hb: haemoglobin; FCM: ferric carboxymaltose; FDI: ferric derisomaltose; GI: gastrointestinal; wks: weeks. *Single dose range for each preparation of intravenous iron. The iron need estimation can be performed using a Simplified Table (that uses patients weight and haemoglobin) for FCM or FDI from their respective Summary of Product Characteristics, or Ganzoni formula for FDI. For FCM the maximum single dose infusion is 1,000 mg and for FDI it is 20 mg/kg without upper limit. In practice, it is common to see 500 mg intervals used since this tracks with the respective Simplified Tables, and there are 500 mg and 1,000 mg vials.

References

    1. Núñez J, Comín-Colet J, Miñana G, et al. Iron deficiency and risk of early readmission following a hospitalization for acute heart failure. Eur J Heart Fail. 2016;18:798–802. doi: 10.1002/ejhf.513. - DOI - PubMed
    1. Graham FJ, Friday JM, Pellicori P, et al. Assessment of haemoglobin and serum markers of iron deficiency in people with cardiovascular disease. Heart. 2023;109:1294–301. doi: 10.1136/heartjnl-2022-322145. - DOI - PMC - PubMed
    1. Masini G, Graham FJ, Pellicori P, et al. Criteria for iron deficiency in patients with heart failure. J Am Coll Cardiol. 2022;79:341–51. doi: 10.1016/j.jacc.2021.11.039. - DOI - PubMed
    1. WHO . Vitamin and mineral nutrition Information system. Geneva, Switzerland: World Health Organization; 2011. Haemoglobin concentrations for the diagnosis of anaemia and assessment of severity.http://scholar.google.com/scholar?hl=en&btnG=Search&q=intitle:Haemoglobi... Available.
    1. McDonagh TA, Metra M, Adamo M, et al. Corrigendum to: 2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure: developed by the task force for the diagnosis and treatment of acute and chronic heart failure of the European society of cardiology (ESC) with the special contribution of the heart failure association (HFA) of the ESC. Eur Heart J. 2021;42:4901. doi: 10.1093/eurheartj/ehab670. - DOI - PubMed

MeSH terms